GLP-1 Consumer Research

Nine published four-dose 1 mg Ozempic benchmarks standardized across markets, with local price basis, dated ECB conversions, comparability rules, and source conflicts documented.

Sourced U.S. Ozempic injection list-price history from 2017 through the announced 2027 WAC, with estimated net prices, self-pay, Medicare, Oregon and CPI benchmarks.

A regulator-sourced register of 30 Ozempic identifiers from FDA, WHO, and national alerts, paired with the exact serial, label, device, market, or carton condition that matters.

Verified 2026 payer policy register comparing BMI floors, comorbidities, lifestyle requirements, initial authorization periods, renewal thresholds, and official source documents.

Published denial triggers across eight exact 2026 insurer and pharmacy-benefit policy instances, with BMI routes, prerequisites, continuation rules, appeal records, and source documents.

CMS Medicare Part D gross GLP-1 drug costs by prescriber state in 2024, with a 2023 comparison, product rankings, methodology, limitations, and downloadable data.

SEC-sourced ledger of funding rounds, acquisitions, public-company revenue, valuations, restructurings, and litigation in GLP-1 telehealth. Confidence-graded, CSV download, updated monthly.

Comprehensive statistics on GLP-1 usage, cost, clinical outcomes, and consumer experience. Sourced from KFF, CDC, IQVIA, CMS, and peer-reviewed trials.

Live telehealth provider pricing tracker with historical data, trend analysis, and change logs.

How many users hide their GLP-1 use and the social dynamics of weight loss medication.

Financial sacrifices, insurance barriers, and out-of-pocket costs for GLP-1 medications.

Self-reported changes in alcohol consumption, food cravings, and compulsive behaviors.

Self-reported experiences, weight regain data, and reasons for discontinuing GLP-1 medications.

How surveyed U.S. adults view GLP-1 users and the impact on dating and relationships.